Antibodies, Monoclonal, Humanized
"Antibodies, Monoclonal, Humanized" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab.
| Descriptor ID |
D061067
|
| MeSH Number(s) |
D12.776.124.486.485.114.224.060 D12.776.124.790.651.114.224.060 D12.776.377.715.548.114.224.200
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Monoclonal, Humanized".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Blood Proteins [D12.776.124]
- Immunoproteins [D12.776.124.486]
- Immunoglobulins [D12.776.124.486.485]
- Antibodies [D12.776.124.486.485.114]
- Antibodies, Monoclonal [D12.776.124.486.485.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.486.485.114.224.060]
- Serum Globulins [D12.776.124.790]
- Immunoglobulins [D12.776.124.790.651]
- Antibodies [D12.776.124.790.651.114]
- Antibodies, Monoclonal [D12.776.124.790.651.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.790.651.114.224.060]
- Globulins [D12.776.377]
- Serum Globulins [D12.776.377.715]
- Immunoglobulins [D12.776.377.715.548]
- Antibodies [D12.776.377.715.548.114]
- Antibodies, Monoclonal [D12.776.377.715.548.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.377.715.548.114.224.200]
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Monoclonal, Humanized".
This graph shows the total number of publications written about "Antibodies, Monoclonal, Humanized" by people in this website by year, and whether "Antibodies, Monoclonal, Humanized" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
| 2002 | 0 | 4 | 4 |
| 2003 | 0 | 2 | 2 |
| 2004 | 0 | 2 | 2 |
| 2005 | 0 | 8 | 8 |
| 2006 | 0 | 5 | 5 |
| 2007 | 0 | 5 | 5 |
| 2008 | 0 | 11 | 11 |
| 2009 | 0 | 10 | 10 |
| 2010 | 0 | 13 | 13 |
| 2011 | 5 | 14 | 19 |
| 2012 | 5 | 8 | 13 |
| 2013 | 6 | 6 | 12 |
| 2014 | 10 | 8 | 18 |
| 2015 | 4 | 9 | 13 |
| 2016 | 4 | 13 | 17 |
| 2017 | 7 | 12 | 19 |
| 2018 | 9 | 9 | 18 |
| 2019 | 15 | 12 | 27 |
| 2020 | 18 | 17 | 35 |
| 2021 | 24 | 9 | 33 |
| 2022 | 8 | 20 | 28 |
| 2023 | 5 | 23 | 28 |
| 2024 | 29 | 13 | 42 |
| 2025 | 21 | 6 | 27 |
| 2026 | 3 | 1 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antibodies, Monoclonal, Humanized" by people in Profiles.
-
Dupilumab for Chronic Hand Eczema: A Systematic Review and Meta-Analysis. Dermatitis. 2026 Jan; 37(1):20-41.
-
2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Vilobelimab. Clin Infect Dis. 2026 Jan 16; 81(Supplement_3):i13-i16.
-
Linavonkibart and pembrolizumab in immune checkpoint blockade-resistant advanced solid tumors: a phase 1 trial. Nat Med. 2026 Mar; 32(3):992-1001.
-
Multiomic Factor Analysis for Pathologic Complete Response after Pembrolizumab + Trastuzumab + Pertuzumab in HER2-Enriched Early Breast Cancer: WSG-Keyriched-1 Trial. Clin Cancer Res. 2026 Jan 06; 32(1):214-223.
-
Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer. N Engl J Med. 2026 Feb 05; 394(6):551-562.
-
Feasibility of Atezolizumab in Combination With Chemotherapy for Children With Relapsed or Refractory Solid Tumors. Pediatr Blood Cancer. 2025 Dec; 72(12):e32046.
-
A Phase I, Open-Label, Dose Escalation Study of Enoblituzumab in Children and Young Adults with B7-H3-Expressing Relapsed or Refractory Solid Tumors. Cancer Res Commun. 2025 Sep 01; 5(9):1574-1583.
-
Autoantibody profiling to predict response to the anti-PD-1 therapy, pembrolizumab, in rare tumors. ESMO Open. 2025 Aug; 10(8):105518.
-
Intratumoral vidutolimod as monotherapy or in combination with pembrolizumab in patients with programmed cell death 1 blockade-resistant melanoma: Final analysis from a phase 1b study. Cancer. 2025 Aug 01; 131(15):e70022.
-
Precemtabart tocentecan, an anti-CEACAM5 antibody-drug conjugate, in metastatic colorectal cancer: a phase 1 trial. Nat Med. 2025 Oct; 31(10):3504-3513.